Roche’s Genentech returns Alzheimer’s assets to AC Immune, cutting 18-year tie to the biotech

Genentech is walking away from an 18-year relationship with AC Immune, handing back global rights to a pair of Alzheimer’s disease drug candidates after suffering a series of setbacks in the clinic.